Marvel Biosciences Corp.: Marvel Biosciences Announces Proxy Tabulation and Shareholder Meeting Results

Calgary, Alberta--(Newsfile Corp. - February 15, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased

Related Keywords

Burlington ,Newfoundland ,Canada ,Canadian ,Jeremy Fehr ,J Roderick Matheson ,Neila Johnson ,Harry Nijjar ,Gordon Bell ,Joanne Yan ,Jacqueline Groot ,Neil Johnson ,Kostenloser Wertpapierhandel ,S Randall Smallbone ,Mark Williams ,Odyssey Trust Company ,Marvel Biosciences Corp ,Income Fund ,Compensation Committee ,Company Advisory Board ,Audit Committee ,Decoma International Inc Magna ,Company Articles ,Alberta Newsfile Corp ,Venture Exchange ,Regulation Services Provider ,Company Or Marvel ,Hyd Industries Inc ,Marvel Biotechnology Inc ,Migao Corporation ,Virtus Advisory Group ,Board Of Norcast Income Fund ,Burlington Economic Development Corporation ,Astron Connect Inc ,Entourage Health Corp ,Public Companies ,Hanwei Energy Services Corp ,Special Meeting ,New Form ,Stock Option ,Option Grants ,Astron Connect ,Joseph Brant ,Hanwei Energy Services ,Advisory Board ,Pneu Hyd Industries ,Decoma International Inc ,Magna International Inc ,Norcast Income Fund ,Roderick Matheson ,Chief Executive ,Chief Science ,Management Information Circular ,Chief Executive Officer ,Marvel ,Iosciences ,Orp ,Nnounces ,Proxy ,Fabulation ,Shareholder ,Meeting ,Results ,